BioSpace News Archive

Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939) announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults.

The U.S. Food and Drug Administration released a national strategy outlining actions the agency will take immediately to help ensure one of the nation’s most vulnerable populations continue to have access to safe, nutritious infant formula and to increase resiliency of the U.S. infant formula market and supply.

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision-making in the EP lab, is proud to announce the achievement of significant milestones demonstrating both the clinical and commercial success of the ECGenius™ System.

Bayer and the agricultural biotech company Oerth Bio announced a new collaboration seeking to develop the next generation of more sustainable crop protection products.

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), earned the esteemed 2023 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service.

Lunaphore today announced the launch of a full expansion of its product offering to provide a universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research.

Biodexa Pharmaceuticals PLC announces that it has issued to various US investors 7,473,095 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 848,068 A Warrants and 646,551 B Warrants received yesterday.

Henry Schein, Inc. announced its presence at the 2023 ADSO Annual Summit, including thought-leadership presentations on the future of dentistry and intrapreneurship as well as activities to support communities in need.

PharmaForce International recently published a report in December that benchmarked the leading Immunology sales and marketing organizations in the United States.

Today, in response to the White House Cancer Moonshot, the Digital Medicine Society (DiMe) and Moffitt Cancer Center announced they are co-hosting CancerX, a new public-private partnership effort to rapidly accelerate the pace of cancer innovation in the U.S., alongside the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH).